MSLE
Income statement / Annual
Last year (2025), Satellos Bioscience Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Satellos Bioscience Inc's net income was -$24.87 M.
See Satellos Bioscience Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$5.09 K
|
$19.99 K
|
$5.28 K
|
$3.73 M
|
$166.94 K
|
$892.78 K
|
$3.15 K
|
$1.53 K
|
$23.83 K
|
$27.62 K
|
| Gross Profit |
-$5.09 K
|
-$19.99 K
|
-$5.28 K
|
-$3.73 M
|
-$166.94 K
|
-$892.78 K
|
-$3.15 K
|
-$1.53 K
|
-$23.83 K
|
-$27.62 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$18.43 M
|
$13.66 M
|
$6.65 M
|
$3.73 M
|
$2.00 M
|
$892.78 K
|
$942.49 K
|
$1.42 M
|
$798.52 K
|
$568.80 K
|
| General & Administrative Expenses |
$7.44 M
|
$5.16 M
|
$4.57 M
|
$4.69 M
|
$2.62 M
|
$813.06 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$174.47 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.44 M
|
$5.16 M
|
$4.57 M
|
$4.69 M
|
$2.62 M
|
$987.53 K
|
$1.32 M
|
$777.27 K
|
$672.54 K
|
$643.78 K
|
| Other Expenses |
$595.00 K
|
$554.63 K
|
$442.49 K
|
-$3.73 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$26.46 M
|
$19.38 M
|
$11.66 M
|
$4.69 M
|
$4.63 M
|
$1.88 M
|
$2.26 M
|
$2.19 M
|
$1.47 M
|
$1.21 M
|
| Cost And Expenses |
$26.46 M
|
$19.38 M
|
$11.66 M
|
$8.43 M
|
$6.65 M
|
$2.77 M
|
$2.27 M
|
$2.19 M
|
$1.49 M
|
$1.24 M
|
| Interest Income |
$1.36 M
|
$955.27 K
|
$1.00 M
|
$63.00 K
|
$6.26 K
|
$0.00
|
$0.00
|
$415.68
|
$6.50 K
|
$16.71 K
|
| Interest Expense |
$0.00
|
$0.00
|
$133.42 K
|
$0.00
|
$772.80 K
|
$499.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$5.00 K
|
$13.94 K
|
$5.28 K
|
$337.00 K
|
$166.94 K
|
$422.00
|
$3.15 K
|
$1.53 K
|
$23.83 K
|
$27.62 K
|
| EBITDA |
-$26.45 M |
-$19.56 M |
-$11.84 M |
-$8.09 M |
-$4.72 M |
-$1.61 M |
-$2.26 M |
-$2.19 M |
-$1.47 M |
-$1.21 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.76 M
|
-$202.76 K
|
-$321.12 K
|
-$2.89 M
|
-$8.86 M
|
$1.19 M
|
$2.72 K
|
$497.53 K
|
$239.49 K
|
-$260.71 K
|
| Income Before Tax |
-$24.70 M
|
-$19.58 M
|
-$11.98 M
|
-$11.32 M
|
-$15.51 M
|
-$1.58 M
|
-$2.26 M
|
-$1.70 M
|
-$1.26 M
|
-$1.50 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$172.00 K
|
$0.00
|
$0.00
|
$5.00 K
|
$0.00
|
$0.00
|
-$272.01 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$24.87 M
|
-$19.58 M
|
-$11.98 M
|
-$11.32 M
|
-$15.51 M
|
-$1.58 M
|
-$1.99 M
|
-$1.70 M
|
-$1.26 M
|
-$1.50 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-20.4 |
-2.16 |
-1.63 |
-3.81 |
-6.02 |
-1.07 |
-3.9 |
-4.82 |
-2.44 |
-4.84 |
| EPS Diluted |
-20.4 |
-2.16 |
-1.63 |
-3.81 |
-6.02 |
-1.07 |
-3.9 |
-4.82 |
-2.44 |
-4.84 |
| Weighted Average Shares Out |
$1.22 M
|
$9.56 M
|
$7.20 M
|
$2.97 M
|
$2.01 M
|
$1.48 M
|
$510.06 K
|
$351.91 K
|
$351.91 K
|
$351.91 K
|
| Weighted Average Shares Out Diluted |
$1.22 M
|
$9.56 M
|
$7.20 M
|
$2.97 M
|
$2.01 M
|
$1.48 M
|
$510.06 K
|
$351.91 K
|
$351.91 K
|
$351.91 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
